These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 33892054)

  • 1. Improving kidney targeting: The influence of nanoparticle physicochemical properties on kidney interactions.
    Huang Y; Wang J; Jiang K; Chung EJ
    J Control Release; 2021 Jun; 334():127-137. PubMed ID: 33892054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting strategies for drug delivery to the kidney: From renal glomeruli to tubules.
    Liu CP; Hu Y; Lin JC; Fu HL; Lim LY; Yuan ZX
    Med Res Rev; 2019 Mar; 39(2):561-578. PubMed ID: 30136283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease.
    Wang J; Masehi-Lano JJ; Chung EJ
    Biomater Sci; 2017 Jul; 5(8):1450-1459. PubMed ID: 28516997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiological principles underlying the kidney targeting of renal nanomedicines.
    Huang Y; Ning X; Ahrari S; Cai Q; Rajora N; Saxena R; Yu M; Zheng J
    Nat Rev Nephrol; 2024 Jun; 20(6):354-370. PubMed ID: 38409369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on Genetic Kidney Diseases: A Call for Drug Delivery and Nanomedicine Solutions.
    Trac N; Ashraf A; Giblin J; Prakash S; Mitragotri S; Chung EJ
    ACS Nano; 2023 Apr; 17(7):6165-6177. PubMed ID: 36988207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in nanotechnology-based drug delivery systems for the kidney.
    Oroojalian F; Charbgoo F; Hashemi M; Amani A; Yazdian-Robati R; Mokhtarzadeh A; Ramezani M; Hamblin MR
    J Control Release; 2020 May; 321():442-462. PubMed ID: 32067996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicines for Renal Management: From Imaging to Treatment.
    Jiang D; Rosenkrans ZT; Ni D; Lin J; Huang P; Cai W
    Acc Chem Res; 2020 Sep; 53(9):1869-1880. PubMed ID: 32786331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A quantitative review of nanotechnology-based therapeutics for kidney diseases.
    Cheng HT; Ngoc Ta YN; Hsia T; Chen Y
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(2):e1953. PubMed ID: 38500369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of size, charge, and peptide ligand length on kidney targeting by small, organic nanoparticles.
    Huang Y; Jiang K; Zhang X; Chung EJ
    Bioeng Transl Med; 2020 Sep; 5(3):e10173. PubMed ID: 33005739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted nanotherapy for kidney diseases: a comprehensive review.
    Sabiu G; Kasinath V; Jung S; Li X; Tsokos GC; Abdi R
    Nephrol Dial Transplant; 2023 May; 38(6):1385-1396. PubMed ID: 35945647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the Kidneys at the Nanoscale: Nanotechnology in Nephrology.
    Vasylaki A; Ghosh P; Jaimes EA; Williams RM
    Kidney360; 2024 Apr; 5(4):618-630. PubMed ID: 38414130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting therapeutics to the glomerulus with nanoparticles.
    Zuckerman JE; Davis ME
    Adv Chronic Kidney Dis; 2013 Nov; 20(6):500-7. PubMed ID: 24206602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding nanoparticle-liver interactions in nanomedicine.
    He Y; Wang Y; Wang L; Jiang W; Wilhelm S
    Expert Opin Drug Deliv; 2024 Jun; 21(6):829-843. PubMed ID: 38946471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Application of Nanoparticles in Diagnosis and Treatment of Kidney Diseases.
    Paluszkiewicz P; Martuszewski A; Zaręba N; Wala K; Banasik M; Kepinska M
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles.
    Ernsting MJ; Murakami M; Roy A; Li SD
    J Control Release; 2013 Dec; 172(3):782-94. PubMed ID: 24075927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting kidney mesangium by nanoparticles of defined size.
    Choi CH; Zuckerman JE; Webster P; Davis ME
    Proc Natl Acad Sci U S A; 2011 Apr; 108(16):6656-61. PubMed ID: 21464325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Charge barriers in the kidney elimination of engineered nanoparticles.
    Huang Y; Yu M; Zheng J
    Proc Natl Acad Sci U S A; 2024 Jun; 121(23):e2403131121. PubMed ID: 38805267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The development of novel tumor targeting delivery strategy].
    Gao HL; Jiang XG
    Yao Xue Xue Bao; 2016 Feb; 51(2):272-80. PubMed ID: 29856581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into Active Targeting of Nanoparticles in Drug Delivery: Advances in Clinical Studies and Design Considerations for Cancer Nanomedicine.
    Pearce AK; O'Reilly RK
    Bioconjug Chem; 2019 Sep; 30(9):2300-2311. PubMed ID: 31441642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.